Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated...
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million...
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE)...
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
MIDDLETON, Wis., July 22, 2025 /PRNewswire/ -- Natus Medical Incorporated is continuing its commitment to innovation and expanding the functionality of...
Powering Alzheimer's research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more...
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products...
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE...
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or...
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA....
Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA....
—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13...
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland -...
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,...
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July...